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Correction of glucose intolerance and the impaired insulin release of
chrome renal failure by verapamil. Insulin release from pancreatic islets
is impaired in chronic renal failure (CRF), and this is due to the state of
secondary hyperparathyroidism of CRF. This defect in association with
resistance to the peripheral action of insulin-caused glucose intolerance
in CRF. It has been suggested that the impaired insulin release induced
by excess parathyroid hormone (PTH) is related to the ability of the
hormone to augment calcium entry into the pancreatic islets, resulting
in accumulation of calcium in the pancreas. Therefore, a calcium
channel blocker may antagonize this effect of PTH, and hence normal-
ize glucose tolerance in CRF. The present study examined this postu-
late by studying intravenous glucose tolerance and insulin release from
pancreatic islets in normal and CRF rats and in CRF animals treated
with the calcium channel blocker, verapamil. Rats with 42 days of CRF
displayed impaired glucose tolerance, significant reduction (P < 0.01) in
insulin release by islets, and doubling of calcium content of the
pancreas (P < 0.01) as compared to normal rats. Simultaneous treat-
ment of CRF rats with verapamil for 42 days resulted in normal glucose
tolerance, higher blood insulin levels during glucose infusion, normal
calcium content of the pancreas, and normal insulin secretion by the
islets. Treatment of normal rats with verapamil for 42 days did not affect
any of the parameters studied. The results show that the calcium
channel blocker, verapamil, by preventing calcium accumulation in the
pancreas, reversed the abnormalities in insulin release that occur in
CRF. This effect allowed a greater rise in blood levels of insulin during
glucose infusion in CRF rats, These higher levels of insulin overcame
the peripheral resistance to its action, and hence normalized glucose
tolerance in CRF.
Carbohydrate intolerance is common in patients [1] and
animals [2, 3] with chronic renal failure. This is due to periph-
eral resistance to the action of insulin [4] and to inappropriate
insulin secretion in response to the insulin resistant state [1, 5,
6]. We [2] and others [6, 7], utilizing euglycemic and hypergly-
cemic clamp techniques, found that the state of secondary
hyperparathyroidism of CRF [2, 8, 9] impairs the ability of the
pancreas to secrete insulin but does not affect the resistance to
the peripheral action of this hormone. Hence, excess blood
levels of parathyroid hormone (PTH) play an important role in
the genesis of carbohydrate intolerance of CRF through the
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action of the hormone on insulin release. Indeed, prevention or
correction of hyperparathyroidism in CRF by parathyroidec-
tomy [2, 6] or by medical suppression of the parathyroid gland
activity [7] was associated with normalization of the glucose
intolerance.
Additional studies from our laboratory [3] demonstrated that
insulin secretion from perfused pancreatic islets obtained from
rats with CRF is indeed impaired. In contrast, islets from
parathyroidectomized CRF rats secreted insulin similar to
normal islets. In addition, impaired insulin secretion was dis-
played by islets from rats with normal renal function treated
with intact PTH. These observations clearly documented a
direct effect of excess PTH on insulin secretion by the pancre-
atic islets, and further showed that this action of PTH may be
related to the PTH-induced calcium accumulation in the pan-
creas.
If this is the case, one should be able to normalize pancreatic
insulin secretion and reverse glucose intolerance of CRF by
preventing calcium accumulation in the pancreas even if the
state of secondary hyperparathyroidism is not corrected. Such
a goal may be achieved by the use of a calcium channel blocker.
The present study was undertaken to examine the effects of
chronic treatment with the calcium channel blocker, verapamil,
on glucose tolerance of rats with CRF and on insulin release by
the pancreatic islets of these rats.
Method
Male Sprague-Dawley rats weighing 275 to 350 g were stud-
ied. They were fed normal rat chow diet (ICN nutritional
Biochemical, Cleveland, Ohio, USA) throughout the study and
allowed to drink ad libitum. Experiments were performed in
four groups of animals: a) normal rats (normal), b) normal rats
receiving verapamil (normal-VER), c) rats with chronic renal
failure (CRF), and d) CRF rats receiving verapamil (CRF-
VER). CRF was produced by two-stage 5/6 nephrectomy. The
animals underwent right partial nephrectomy through a flank
incision; a week later, a left nephrectomy was performed.
Verapamil (0.1 p,g/g body wt) dissolved in saline was given to
one group of normal animals and of CRF rats twice daily
through subcutaneous injections. The other normal and CRF
rats received subcutaneous injections twice daily of vehicle
(saline) only. Previous studies in our laboratory showed that
glucose intolerance and abnormal insulin release occurred after
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six weeks of CRF [31. Therefore the experiments in the present
study were performed after 42 days of CRF or verapamil
treatment.
In one part of the study, a one-hour intravenous glucose
tolerance test (IVGTT) was done in normal, normal-VER, CRF
and CRF-VER rats. The animals were not fasted before the
test. The jugular vein and carotid artery were cannulated with
PE 10 tubing under general anesthesia with ketamine-HC1 75
mg/kg body wt (Bristol Laboratories, Syracuse, New York,
USA). The animals were allowed to recover from the surgical
procedure and were studied 12 hours later in the awake state.
The rats received 0.5 g of D-glucose/kg body wt in a bolus
intravenous injection. A total of eight blood samples of 60 sl
each were collected serially before and at 5, 15, 30, 45 and 60
minutes after glucose injection from the arterial line for the
measurement of glucose and insulin.
In another part of the study, the animals were sacrificed by
decapitation and the pancreas was dissected free of adipose
tissue. The islets were isolated by the collagenase digestion
method of Lacy and Kostianovsky [10] and picked free of
exocrine tissue under a dissecting microscope. Both static and
dynamic studies were done according to methods previously
described [11, 12].
Briefly, in the static studies the islets were preincubated for a
period of 30 minutes at 37°C in a modified Krebs-Ringer
bicarbonate buffer (pH 7.4) containing 10 mM HEPES and 0.5
mgldl bovine serum albumin (incubation media) and 2.8 mrt
D-glucose. The islets were then matched for size by visual
inspection and groups of 10 islets were incubated in tubes
containing 1.0 ml of the incubation media and were studied with
the following secretogogues: a) 2.8 m'vi D-glucose, b) 16.7 mM
D-glucose, c) 100 sM isobutyl-l-Methylxanthine (IBMX) and
16.7 m D-glucose, and d) 10 tM forskolin and 16.7 mri
D-glucose. After 30 minutes of incubation in a shaker bath at
37°C, the supernatants were aspirated for determination of
insulin.
The dynamic studies were conducted in a four channel
perifusion apparatus utilizing previously described methods
[11, 12]. Twenty-five size-matched islets were placed in each of
the four conical chambers of 0.07 ml capacity and were peri-
fused at a rate of 0.8 mI/mm with the incubation media contain-
ing 2.8 m D-glucose at a temperature of 37°C and a gas
mixture of 95% 02 and 5% CO2 being continuously bubbled into
the perifusate. After leaving the chambers, the perfusate was
filtered through 8.0 pm pore size filter (Sartorius Burlingame,
California, USA) and was collected. Each study was performed
in duplicates. After 39 minutes of pre-incubation, the collection
of the effluent was started and continued at a one minute
interval for 41 minutes. The first six collections (6 mm) repre-
sented the basal level of insulin release during perifusion with
2.8 m D-glucose. Thereafter, the D-glucose concentration in
the perifusate was increased to 16.7 m and an additional 35
samples were collected. Insulin concentration was then deter-
mined in the various samples of the effluent.
In the dynamic studies of insulin release, the changes from
baseline with time were examined by calculating the area under
the curve for each study. Insulin release started to increase four
minutes after the change of the concentration of D-glucose in
the perifusate to 16.7 m. Therefore, the average values of
insulin release during the six minutes prior to the change in
glucose concentration and the four minutes immediately there-
after were used as a baseline level. The calculation of the areas
under the curve allowed us to estimate insulin release during the
initial phase (5 mm between mm 4 and 9) and the total insulin
release (31 mm between mm 4 and 35).
Calcium content of the pancreas was also measured. About
0.5 to 1.0 g of pancreas was placed in tarred porcelain crucibles
and weighed to 0.01 mg. All samples were dried at 105°C for 48
hours and then reweighed to determine water content. Samples
were then ashed for 12 hours in an oven with 700°C. The
samples were then extracted in 0.75 N HNO3 for 24 hours and
calcium concentration was determined. The measurement of
calcium was made with Perkin Elmer atomic absorption spec-
trophotometer, Model 503 (Perkin Elmer Corp., Norwalk,
Connecticut, USA), those of creatinine and phosphorus with
Technicon autoanalyzer (Technicon Instrument Inc., Tarry-
town, New York, USA), and those of glucose by glucose
oxidase method utilizing Beckman glucose analyzer II (Beck-
man Instrument, Inc., Fullerton, California, USA). Insulin was
determined by charcoal-coated radioimmunoassay using rat
insulin as standard [13].
Statistical analysis was done with the Clinfo computer sys-
tem. The data were presented as mean SE. Changes from
baseline in parameters with mutiple measurements with time
(plasma, glucose, and insulin during IVGTT and dynamic
insulin release) were evaluated by calculating area under the
curve for each experiment utilizing the trapezoidal rule. The
areas under the curve as well as the data from studies of static
insulin release were analyzed by one-way analysis of variance
and compared with each other using the Duncan multiple range
test. Non-parametric analysis was also done using Wilcox
non-paired rank sum tests adjusted for multiple comparison.
Results
IVGTT studies
Table 1 provides the data on blood chemistry for the animals
which were studied with IVGTT and Figures 1 and 2 show the
changes in plasma glucose and insulin during the 60 minutes of
the test, respectively. The nephrectomy procedure resulted in a
significant (P < 0.01) rise in the plasma levels of creatinine with
the values being three times higher than in normal or normal-
VER rats. There were no significant differences in the plasma
levels of calcium and phosphorus among the various groups of
rats. The plasma levels of potassium in CRF rats were signifi-
cantly (P < 0.01) higher than those of the other three groups.
The body weight of CRF-VER rats was lower than normal but
it was not significantly different from that of CRF rats.
Within five minutes after the injection of glucose load, the
plasma concentration of glucose reached their peak and de-
creased thereafter. The rats with CRF displayed glucose intol-
erance (Fig. 1) with the area under the curve for plasma glucose
significantly (P < 0.01) higher than that of the other three
groups of animals (Table 1). The treatment of CRF rats with
verapamil was associated with a normal glucose tolerance test
and the area under the curve for plasma glucose in the CRF-
VER was not different from that in normal or normal-VER rats.
Verapamil did not affect glucose tolerance in normal animals.
There were significant increments in plasma insulin levels in
all groups of animals (Fig. 2). There was no significant differ-
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Table 1. Body weight, blood chemistry and area under the curve for plasma glucose and insulin in the various groups of rats studied with
intravenous gIucose tolerance test
Body
weight
g
Creatinine
Plasma
calcium Phosphorus Potassium
Area under the IVGTT curve
plasma glucose
mg/dl. 60 mm
plasma insulin
pg/rn! 60 mmmg/dl
Normal N = 4 398 8 0.55 0.01 9.5 0.48 6.9 0.30 4.20 0.10 6528 468 75 5
Normal-VER 369 13 0.52 0.02 9.9 0.33 6.0 0.11 4.25 0.12 6143 144 79 1
N= 5
CFRN = 4 350 13 1.58 0.09a 10.4 0.33 6.4 0.50 5.30 0.09k' 9065 199b 118
CRF-VER 332 7 1,66 0.04a 10.3 0.32 6.6 0.28 4.15 0.15 6990 350 185 18k'
N= 4
Data are presented as mean SE.
a p < 0.01 vs. normal and normal-VERb P < 0.01 vs. all other groups
0
30 40
Time, minutes
Fig. 1. The changes in plasma glucose concentration during intrave-
nous glucose tolerance tests. Each data point represents mean value
and brackets denote I SE. Symbols are: (0) normal; (•) normal +
verapamil; (A) CRF; (is) CRF + verapamil.
ence in the changes in the plasma insulin levels between normal
and normal-VER rats. In the CRF animals, plasma insulin
concentrations increased from 0.9 0.06 pg/mI to a peak of 4.0
0.67 pg/mi and remained elevated to a lesser degree through-
out the study. In the CRF-VER rats, the maximum increment in
plasma insulin concentration (from 0.8 0.06 to 5.80 0.41
pg/mI) was significantly (P < 0.01) higher than that observed in
CRF rats. The levels then gradually decreased but were always
higher than those in CRF rats. The area under the curve for
plasma insulin in the studies in CRF-VER was also significantly
(P < 0.01) higher than in CRF rats (Table 1).
Insulin release by pancreatic islets
The biochemical data, insulin release during static studies,
calcium content of the pancreas and insulin secretion during
dynamic studies in normal, normal-VER, CRF and CRF-VER
rats are shown in Table 2 and Figures 3 and 4. The CRF and
CRF-VER rats had significantly (P < 0.01) higher plasma levels
of creatinine than normal and normal-VER rats. There were no
significant differences between the plasma concentrations of
calcium and phosphorus among the various groups of animals.
Insulin release induced by 16.7 mr'i D-glucose during static
studies in CRF rats (51 2 pg/islet/mm) was significantly (P <
0.01) lower than that in normal (148 13 pg/islet/mm), normal-
VER (151 14 pg/islet/mm) and CRF-VER (115 4 pg/
islet/mm) (Fig. 3). Both IBMX and forskolin produced signifi-
cant (P < 0.01) rise in insulin secretion, and the increments over
that produced by 16.7 m glucose alone were not significantly
different (Fig. 3) in the four groups of rats.
Insulin release during the dynamic studies is shown in Figure
4. It is evident that insulin release in CRF rats was lower than
normal, normal-VER, and CRF-VER rats. Indeed the areas
under the curve for both the early and total insulin release in
500
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Fig. 2. The changes in plasma levels of insulin during intravenous
glucose tolerance test. Each data point represents mean value and
brackets denote I SE. Symbols are (0) normal; (•) normal + verapamil;
(A) CRF; () CRF + verapamil.
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Table 2. Body weight, blood chemistry, insulin release and pancreatic calcium content in various groups of rats studied with the isolated
perfused islet technique
Body
weight
g
Plasma mgldl
Insulin release pg/islet .Pancreatic
calcium
g/kg dry wt
Phase 1 Total
(5 mm) (31 mm)Cr Ca P
Normal N 6 389 9 0.55 0.05 9.5 0.48 6.3 0.80 323 39 3816 221 4.7 0.15
Normal-VER 396 11 0.52 0.02 9.2 0.32 6.5 0.70 339 19 3748 206 4.5 0.28
N=6
CRF N = 5 353 ll 1.89 0.l9' 9.5 0.32 5.9 0.52 42 13" 1073 208" 10.8 0.90"
CRF-VER 329 l2 1.87 0.16a 9.7 0.33 6.2 0.74 170 2? 3045 288 5.1 0.44
N=6
Data are presented as mean si. Abbreviations are: Cr, creatinine; Ca, calcium; P, phosphorus.
a p < 0.01 vs. normal and normal-VER
"P < 0.01 vs. all other groups
J.
Ca
C
CRF rats were significantly (P < 0.01) lower than those in the
other three groups of animals (Table 2). Although treatment of
CRF rats with verapamil was associated with a significantly
higher first-phase insulin release, the values were still signifi-
cantly (P < 0.01) lower than those in normal or normal-VER
animals; however, total insulin release in CRF-VER rats was
not different from normal or normal-VER animals. The calcium
content of the pancreas in CRF rats was significantly (P < 0.01)
higher than that of normal, normal-VER and CRF-VER ani-
mals. There were no significant differences in the calcium
content of the pancreas among the latter three groups of
animals. Thus, treatment of CRF animals with verapamil pre-
vented the accumulation of calcium in the pancreas.
Discussion
The results of the present study demonstrate that treatment
of CRF rats for six weeks with verapamil corrected the glucose
intolerance. This conclusion implies that the area under the
curve for plasma glucose during IVGTT in CRF rats treated
with verapamil is not different from that of normal rats treated
with this drug. Indeed, analysis of the data confirm the absence
Time, minutes
Fig. 4. Dynamic insulin release from perfused pancreatic islets. Each
data point depicts mean value and brackets represents 1 SE. Symbols
are: (0) normal; (I) normal + verapamil; (A) CRF; () CRF +
verapamil.
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Fig. 3. Insulin release from pancreatic islets
during studies with static incubation. Each
column represents mean value and brackets
denote I SE. Symbols are: (11111) 2.8 ms
glucose; () 16.7 m glucose; (•) 16.7 mM
glucose + 100 M IBMX; (LI) 16.7 mss
glucose + 10 M forskolin.
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of a statistically significant difference between the two groups.
However, the mean value in CRF rats treated with verapamil
was somewhat higher than that of the normal animals receiving
verapamil, It is possible, therefore, that the treatment with
verapamil did not completely correct the glucose intolerance of
CRF rats but rather produced marked and significant improve-
ment in this abnormality.
This effect of verapamil is most likely due to the higher blood
levels of insulin after the intravenous glucose injection. These
observations are similar to those reported by us in parathyroid-
ectomized CRF dogs [2] and in CRF humans in whom the
activity of the parathyroid glands was suppressed medically or
in those subjected to PTX [6, 7]. Thus, it appears that reduction
of PTH levels in animals or humans with CRF by medical or
surgical means [6, 7], or that the chronic treatment of CRF rats
with verapamil which does not affect serum levels of PTH [141
permits the pancreas to produce more insulin; such a response
is sufficient to overcome the resistance to the peripheral action
of insulin and results in normal glucose tolerance.
Our studies were not designed to examine the effect of
verapamil on the peripheral resistance to the action of insulin in
CRF. However, our data indicate that CRF-VER rats had a
two- to fivefold increase in serum insulin levels during IVGTT
and normal glucose tolerance as compared to 50% increase in
plasma insulin levels in CRF rats who had abnormal glucose
tolerance. These data clearly suggest that verapamil did not
improve the peripheral resistance to insulin and may even have
worsened it. However, if chronic verapamil administration is
associated with the development or worsening of peripheral
resistance to insulin action, one would expect that glucose
intolerance develops in the normal-VER animals. This did not
occur and these animals had normal glucose tolerance. The
issue of the effect of verapamil treatment on peripheral resis-
tance to insulin could be evaluated by euglycemic insulin clamp
technique, which was not done in our studies.
Most available data indicate that the peripheral resistance to
insulin is not due to alterations in the number or affinity of
insulin receptors but rather due to a post-receptor defect [15].
Since our data is consistent with the notion that the effect of
verapamil on glucose intolerance in CRF is not mediated
through improvement in the peripheral resistance to insulin,
one may assume that the therapy does not improve the post-
receptor defect.
The results of the static studies with forskolin and IBMX
indicate that the reduction in insulin secretion from islets of
CRF rats and the correction of this defect by treatment with
verapamil is not related to an effect on the adenylate cyclase-
cyclic AMP system. An increase in cyclic AMP produced either
by forskolin, which stimulates adenylate cyclase activity [16],
or by IBMX, which inhibits phosphodiesterase activity [17],
caused a similar augmentation in insulin secretion by islets from
normal, normal-VER, CRF and CRF-VER rats.
The plasma levels of insulin during IGVTT in CRF rats were
higher than that in the normal animals, while insulin release
from islets was lower in the former than in the latter group. This
observation seems contradictory. However, it must be empha-
sized that plasma insulin levels represent the balance between
the rate of secretion and that of degradation. Thus, the de-
creased degradation of insulin in CRF [18] is responsible for the
higher insulin levels despite low insulin secretion. In CRF-VER
rats, the higher insulin secretion from the islets combined with
decreased degradation secondary to CRF are responsible for
the significantly higher plasma insulin levels observed in these
rats compared to the untreated CRF animals. It is, theoreti-
cally, possible that verapamil may alter insulin degradation but
neither our study nor others refute or confirm such a possibility.
It has been suggested that excess PTH through its ability to
enhance calcium entry into cells [19—25], causes accumulation
of the calcium in the pancreatic islets [3], and such an effect
could impair the function of these islets, resulting in reduced
insulin release in response to glucose and hence glucose intol-
erance. We have previously reported [31, that the calcium
content of the pancreas of CRF rats with intact parathyroid
glands was significantly higher than that of the normal pancreas.
The calcium content in these CRF rats was normalized by PTX.
These changes in pancreatic calcium correlated with the insulin
release which was impaired from islets of CRF rats but normal
from islets of PTX-CRF animals.
The data of the present study provide further support for this
notion. Again, the calcium content of the pancreas from CRF
rats with intact parathyroid glands was significantly higher than
normal and insulin release from the islets of these animals was
markedly impaired. Chronic treatment of the CRF rats with
verapamil, which does not affect PTH levels [14], prevented the
PTH-induced calcium accumulation in the pancreas by blocking
calcium entry and normalized the glucose-induced insulin re-
lease from the pancreatic islets.
Available data indicate that an acute rise in cytosolic calcium
of islets induces insulin secretion [17, 26—28], and this appears
to vitiate the notion that an increase in pancreatic calcium
inhibited insulin secretion in our studies. However, it is possi-
ble that acute exposure of the pancreatic islets to PTH stimu-
lates glucose-induced insulin release, but chronic exposure to
the hormone and a consequent overloading of the islets with
calcium exerts an inhibitory effect. A corollary to a different
effect of acute or chronic excess of PTH is found in observa-
tions in other systems. The hormone acutely stimulates both the
chronotropic [25] and the inotropic [29] properties of heart cells
and enhances random migration of polymorphonuclear leuco-
cytes [30], but chronic exposure to excess PTH decreases or
stops the beating of heart cells [25], impairs the metabolism and
function of the heart [311 and reduces random migration of the
leucocytes [30].
We suggest that the effect of changes in cytosolic calcium of
the islets on insulin release depends on the magnitude of these
changes and their duration. Such a proposition would imply that
a large and sustained increment in islet calcium could inhibit
insulin release. If the increase in total pancreatic calcium found
in our rats with CRF reflects a higher calcium content in the
cells of both the exocrine and endocrine tissue of the pancreas,
one may assume that calcium overloading of the islets is
present. Under such circumstances, the capacity of the cellular
organelles to sequester calcium and buffer the calcium load may
approach saturation and a new steady state with higher cyto-
solic calcium may develop; in such a setting insulin release may
be inhibited. Indeed, certain data are consistent with the notion
that higher islets cytosolic calcium may reduce insulin release.
Frankel, Atwater and Grodsky [32] demonstrated that high
cytosolic calcium in pancreatic islets may activate potassium
permeability, cause repolarization of the cell membrane and
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blunt insulin release. Also it is known that glucose-induced
insulin release will plateau as cytosolic calcium reaches a
certain level [17]; thus, if the islets of CRF rats have higher
cytosolic calcium than those of normal rats, the critical levels of
cytosolic calcium in islets at which glucose-induced insulin
secretion would plateau could be reached earlier and insulin
release would be limited. Verapamil, by correcting calcium
accumulation in the pancreas and presumably in the islets of
CRF rats, would reverse the abnormalities in insulin release.
Our proposition requires confirmation with direct measure-
ments of cytosolic calcium.
The observations of the present study may provide a thera-
peutic approach for the control of glucose intolerance of CRF.
However, it must be mentioned that in our study verapamil was
given simultaneously with the induction of CRF. It is possible
that verapamil may not correct glucose intolerance if it is given
to animals or humans with established CRF. In such a situation,
it may not be possible to reverse the changes in pancreatic
calcium. However, Mak et al. [6, 7] were able to normalize
glucose intolerance in CRF patients after six months of medical
suppression of hyperparathyroidism or PTX, suggesting that
reversal of the pancreatic abnormality is possible. We know of
one study in which dialysis patients were treated for nine weeks
with another calcium channel blocker, nifedipine [33]. Their
blood levels of insulin during the oral glucose tolerance test
were higher than in the patients receiving placebo, but the
difference did not reach statistical significance. It is possible
that a longer period of treatment with the drug is needed to
achieve complete correction of the glucose intolerance by
normalization of the pancreatic response to glucose.
It is well established that verapamil added in vitro to pancre-
atic islets inhibits insulin release by these structures [27, 341.
However, the effects of the in vivo administration of the drug
may differ from those observed in the in vitro experiments.
Indeed, several studies have shown that acute intravenous
infusion of verapamil or oral administration of the drug for
several days did not affect blood levels of insulin during glucose
tolerance tests [35—37]. Others reported a decrease in blood
insulin levels during intravenous infusion of verapamil in hu-
mans [38], dogs [39], or rats [401. It is very difficult to compare
these data describing the effects of acute in vivo administration
of verapamil with our studies which evaluated the chronic in
vivo effect of the drug in animals of CRF. Furthermore, our
results showed that the chronic administration of verapamil to
normal rats does not affect glucose tolerance, blood levels of
insulin or insulin release from the islets of these animals.
Insulin release by the pancreas may be affected by changes in
the concentrations of plasma calcium [41, 42], phosphorus [43,
44] and potassium [45]. An effect of verapamil on these param-
eters may influence insulin release independently of changes in
pancreatic calcium. The differences between the plasma insulin
levels during IVGTT and insulin release from islets between the
normal, CRE, CRF-VER, and normal-VER could not be due to
differences in the plasma concentrations of calcium and phos-
phorus since these two latter parameters were not different
among the various groups. The lower plasma potassium con-
centration in the CRF-VER is most likely due to an effect of
verapamil on extrarenal homeostasis of potassium [46]. This
difference in plasma potassium between CRF-VER and CRF
rats could not explain the effect of verapamil on glucose
intolerance and insulin release in CRF-VER rats. The higher
potassium level in the CRF rats should have been associated
with higher insulin and not lower release since hyperkalemia
stimulates insulin secretion.
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